Chemical inhibitors of ARNO target various aspects of its functional activity, most notably its interaction with ARF GTPases. SecinH3, for instance, directly impedes ARNO's ability to activate ARF GTPases by obstructing their interaction. This disruption is crucial as ARNO serves as a guanine nucleotide exchange factor (GEF), catalyzing the exchange of GDP for GTP on ARF proteins, a step essential for their activation. Brefeldin A, although not a direct inhibitor of ARNO, effectively reduces ARNO-mediated activation of ARF6 by preventing the GDP-GTP exchange on ARF proteins. The compound Exo2 also disrupts ARNO function by targeting the ARF-GEF activation process, specifically at the Golgi apparatus where ARNO is known to operate, thus obstructing the downstream signaling pathways that depend on ARNO's GEF activity.
Further, ZCL278 concentrates on the Sec7 domain of ARNO, a domain paramount for the GTP exchange activity, thereby diminishing ARNO's ability to activate ARF proteins. Simultaneously, LG100754, while primarily recognized as a retinoid X receptor (RXR) antagonist, can alter signaling pathways that may be tangentially connected to ARNO's signaling routes. EHT 1864 and NSC23766, although not direct inhibitors of ARNO, inhibit Rac1 and its interactions with GEFs, which indirectly impacts ARNO-associated pathways reliant on Rac1 for signal propagation. Similarly, ML141 and CASIN target Cdc42, another GTPase that, when inhibited, can attenuate ARNO-mediated signaling due to Cdc42's involvement in actin cytoskeleton organization where ARNO might participate. Lastly, PD168393 and GW5074, though known for inhibiting EGFR tyrosine kinase and c-Raf kinase respectively, can indirectly lessen the activation of downstream pathways that involve ARNO, as these kinases are upstream regulators in signaling cascades that could engage ARNO's GEF activity. Through these various mechanisms, each chemical serves to inhibit the functional activity of ARNO, thereby impeding its role in cellular signaling processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
Inhibits cytohesins, including ARNO, by preventing their interaction with ARF GTPases, leading to reduced ARNO-mediated activation of ARF6. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts ARF protein activation by inhibiting the exchange of GDP for GTP, which indirectly inhibits ARNO function as ARNO is an ARF GEF. | ||||||
Exo2 | 304684-77-3 | sc-215011 sc-215011A | 5 mg 25 mg | $89.00 $288.00 | 1 | |
Disrupts the function of ARNO by inhibiting the ARF-GEF mediated activation of ARF proteins, particularly at the Golgi. | ||||||
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | $213.00 $889.00 | 12 | |
Blocks Rac1 activation and indirectly inhibits ARNO-associated pathways that require Rac1, leading to decreased ARNO-mediated cellular effects. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
Cdc42 inhibitor that indirectly inhibits ARNO by affecting Cdc42-dependent signaling pathways in which ARNO could participate. | ||||||
CASIN | 425399-05-9 | sc-397016 | 10 mg | $460.00 | 1 | |
Inhibits Cdc42, potentially leading to reduced ARNO-mediated signaling due to the role of Cdc42 in actin cytoskeleton reorganization. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
Directly inhibits the interaction between Cdc42 and its GEFs, including ARNO, thereby reducing ARNO-mediated activation of Cdc42. | ||||||
PD 168393 | 194423-15-9 | sc-222138 | 1 mg | $162.00 | 4 | |
Inhibits EGFR tyrosine kinase and can indirectly inhibit ARNO through downstream pathways that involve EGFR signaling. | ||||||